All News

PSO.Palmoplantar.jpg

Biologic Use and the Risk of Serious Infection in Psoriasis Patients

Jack Cush, MD

National Health Data from France examined biologic use in patients with moderate to severe psoriasis, and found the risk of serious infections (SIE) to be increased with some biologics (infliximab and adalimumab), but not others (etanercept, ustekinumab IL-17 and IL-23 inhibitors or apremila

Read Article
RheumNow Podcast square

RheumNow Podcast – Rheumatologist Smoke-Enders (10.22.2021)

Jack Cush, MD

Today I have a few questions: Is tramadol really a weak narcotic? Should we really still be doing placebo-controlled trials? What are we going to do about our patients who are smokers? This and more, in this week's review of the news and journal articles.

Read Article
RheumNow Podcast square

RheumNow Podcast – Jack of All Subspecialties (10.1.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
RheumNow Podcast square

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Jack Cush, MD

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID breakthrough infections, and statin use and the risk of RA, as I review the news and journal articles from the past week on RheumNow.

Read Article
psoriatic.PIP_.JPG

Predictors of Inflammatory Arthritis

Jack Cush, MD

Data from 4 parallel case-control studies within The Health Improvement Network looked at risk factors for developing psoriatic arthritis (PsA), psoriasis, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) showed both shared and differentiating risk factors, but statin use was protective in all 4 conditions.

Read Article
RheumNow Podcast square

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
grappa sign treatment recommendations

ICYMI: New GRAPPA 2021 PsO and PsA Treatment Recommendations

Rachel Tate, DO

The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop recommendations, based upon the best scientific evidence, for the optimal treatment of patients with PsA” Dr. Laura Coates, Oxford detailed in abstract #OP0229. Since the last update in 2015, there have been multiple changes, which are highlighted here.

Read Article
depression oh no HA

Psoriatic arthritis mortality & morbidities

Paul Studenic, MD, PhD

Psoriatic arthritis (PsA) is a chronic condition with manifold clinical presentations. Health issues may be far beyond the classical associated conditions like uveitis, enthesitis etc. The current study of Tillett et al (OP0231) assessed comorbidities and patient characteristics comparing psoriasis patients with or without PsA.

Read Article
KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA: 👉some benefits of risankizumab for axial disease 👉no data regarding bowel disease 👉pts did remain on background DMARDS, steroids. (2/2)

TheDaoIndex KDAO2011 ( View Tweet)

Risankizumab (IL-23i) KEEPsAKE 1 and 2 (phase 3) studies for PsA treatment ⬆️ACR20 response compared to pbo ⬆️secondary endpoints ⭐️no new safety signals Abs#453 #ACR21 #ACRBest @RheumNow https://t.co/7bwvIPMz38 https://t.co/TJaSqwipa5

Links:

Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19. ▶️150 mg RZB vs Placebo ⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI ⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn ⭐️No safety signal https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd

Links:

Eric Dein ericdeinmd ( View Tweet)
KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA: 👉phase 3 DBRPCT 24 weeks 👉150 mg week 0,4, 16 weeks 👉improved ACR20,ACR50,ACR70 👉improved PASI90 👉improved HAQ-DI 👉no increased safety signals #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi
TheDaoIndex KDAO2011 ( View Tweet)
Promising results of Risankizumab for #psoriaticarthritis 🔸Pts significantly achieved higher rates of ACR20, 50 and 70 response at wk 24 vs. placebo 🔸Well tolerated and showed no safety signals @RheumNow #ACR21 #ACRBest abs0453 https://t.co/TDSLEgF68g
sheila RHEUMarampa ( View Tweet)
Abst0453 #ACR21 @RheumNow integrated phase 2/3 trial results of il23 inhibitor Risankizumab (RZB) in PsA: significant improvement ACR20 at Week 24 (RZB 55.5% vs PBO 31.3%, P < 0.001), secondary endpoint met at HAQ DI, PASI, fatigue score& enthesitis. no new safety signals https://t.co/ZAVgswoXCf
Olga Petryna DrPetryna ( View Tweet)
RZB tx resulted in statistically greater improvements in signs/ symptoms of PsA vs PBO and was well tolerated w/ no new safety signals. Plenary Abs 0453 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/c9RJdWlmpO https://t.co/MDbdAhdnIy

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
Richard Conway RichardPAConway ( View Tweet)
Gender differences in AS pts? IL-23R, IL-12R, IL-6R, JAK, STAT and TYK2 ⬇️regulated in men Small study of 20 pts, but could it guide targeted therapy based on gender?🤔 Abs#0050 https://t.co/OQHQCCzfuC #ACR21 @RheumNow

Links:

Robert B Chao, MD doctorRBC ( View Tweet)

ICYMI: Nice full read review of IL-23 in Rheumatology - its biology and clinical targeting. IL-23 is a coordinating cytokine in psoriasis, psoriatic arthritis and inflammatory bowel disease. https://t.co/tDWZuV6Tao https://t.co/0p8RGnnE9B

Links:

Dr. John Cush RheumNow ( View Tweet)
Nice full read review of IL-23 in Rheumatology - its biology and clinical targeting. IL-23 is a coordinating cytokine in psoriasis, psoriatic arthritis and inflammatory bowel disease. https://t.co/tDWZuV6Tao

Links:

Dr. John Cush RheumNow ( View Tweet)

Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis. #RheumNow https://t.co/yLCxyC1oLr https://t.co/Uloqx2phlh

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×